Outlook Therapeutics, Inc. OTLK
0.46 USD 0.00 (+0.28%)
At closeNov 10, 2026, 4:00 PM EST
0.46 0.00 +0.74%
After hours · Nov 10, 4:00 PM ET
0.446 Day range 0.468
0.161 52-week range 2.54
- YTD
- -70.85%
- 1 year
- -63.44%
News
benzinga.com Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal…
benzinga.com Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5 Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
benzinga.com 5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In U.S. stocks fell, but S&P 500 gained 0.4% for 3rd week. Wall Street analysts make new stock picks daily, Benzinga's data can help make better trades.
benzinga.com BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
benzinga.com Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga…
benzinga.com Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the…
benzinga.com S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone CNN Fear & Greed index showed improved market sentiment, with S&P 500 hitting a new record high after PPI data release. Nasdaq up 0.81%.
benzinga.com Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
- benzinga.com Outlook Therapeutics Launches Underwritten Public Offering Of Common Stock And Warrants To Fund LYTENAVA Launch; No Financial Terms Disclosed Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…
benzinga.com HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6 HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved…
benzinga.com Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
benzinga.com This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analyst ratings page before buying.- benzinga.com BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.
benzinga.com Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and…
benzinga.com Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Outlook Therapeutics Says FDA Accepts Resubmitted BLA For ONS-5010/LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration; PDUFA Target Action Date July 29 Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.
benzinga.com Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10 Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Outlook Therapeutics Announces $5M Registered Direct Offering Of 8,539,709 Shares At $0.5855/Share To GMS Ventures For Working Capital And General Corporate Purposes Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the ONS-5010 dispute resolution process.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Wall Street analysts changed ratings on top stocks. Check out the complete list on Benzinga's analyst ratings page. AMAT was downgraded.- benzinga.com Outlook Therapeutics Q2 Adj. EPS $(0.16) Misses $(0.12) Estimate, Sales $128.000K Miss $4.400M Estimate Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 60 percent increase over losses of…
benzinga.com Outlook Therapeutics Terminates Offering Agreement With BTIG Effective May 12 Effective May 12, 2026, Outlook Therapeutics canceled its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the "Prior Sales Agreement") with BTIG, LLC with respect to an…- benzinga.com Outlook Therapeutics Enter $100M Offering Agreement With H.C. Wainwright On May 13, 2026, Outlook Therapeutics, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), pursuant to…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Outlook Therapeutics Completes Federal Dispute Resolution Meeting With The Office Of New Drugs At FDA For Regulatory Nod For ONS-5010 / LYTENAVA Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Crude Oil Gains Around 4%; US Business Activity Declines In March U.S. stocks fall with Dow down 0.46%, S&P 500 down 0.52%, NASDAQ down 0.89%. Energy up 2.5%, communication services down 1.2%.
benzinga.com Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results US stocks lower on Tuesday as Dow falls over 350 points while NASDAQ and S&P 500 also decline. Energy shares up 1.7%, tech stocks down 1.1%.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.
benzinga.com Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session